Literature DB >> 15908510

Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence.

Guibao Gu1, Ichiro Kondo, Xiao-Ying Hua, Tony L Yaksh.   

Abstract

Spinal opiate analgesia is associated with presynaptic inhibition of release of excitatory neurotransmitters/neuromodulators, e.g., substance P (SP), from primary afferent terminals. Chronic intrathecal (i.t.) administration of opiates such as morphine results in an initial analgesia followed by tolerance and a state of dependence. In this study, we examined the resting and evoked neurokinin 1 receptor (NK1r) internalization, indicative of endogenous SP release, in dorsal horn neurons of the lumbar spinal cord by immunocytochemistry during chronic i.t. infusion of morphine in rats. Noxious mechanical stimulation (compression) applied to unilateral hind paw evoked a significant increase in NK1r internalization in lamina I neurons in the ipsilateral dorsal horn. Intrathecal morphine infusion (40 nmol/microl/h) for 1 day possessed similar analgesic efficacy as acute morphine and blocked compression-induced spinal NK1r internalization. After 5 days of morphine infusion, thermal escape latencies were the same as in preinfusion animals or saline-infused controls, and compression-evoked NK1r internalization was no longer suppressed. Systemic administration of naloxone to rats on day 6 of morphine infusion resulted in prominent withdrawal behaviors and a concomitant increase in NK1r internalization in dorsal horn. The naloxone-induced internalization was blocked by NK1r antagonist L-703,606 [cis-2-(diphenylmethyl)-N-[(2-iodophenyl)methyl]-1 azabicyclo[2.2.2]octan-3-amine] or pretreatment with capsaicin, confirming that the internalization is due to the endogenous SP release from the primary afferents. We conclude that inability to suppress release of excitatory neurotransmitters/neuromodulators from primary afferents by morphine after chronic exposure is an important component in spinal morphine tolerance, and excessive release from these afferents contributes to the spinal morphine withdrawal syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908510     DOI: 10.1124/jpet.105.087718

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

1.  Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Vinod Kulkarni; Peg Davis; Shou-Wu Ma; Edita Navratilova; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

2.  Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.

Authors:  Jie Xiao; Si Zeng; Xiangrui Wang; Hasan Babazada; Zhanchun Li; Renyu Liu; Weifeng Yu
Journal:  Transl Perioper Pain Med       Date:  2016

3.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Authors:  T M Largent-Milnes; T Yamamoto; P Nair; J W Moulton; V J Hruby; J Lai; F Porreca; T W Vanderah
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Opioid-receptor-heteromer-specific trafficking and pharmacology.

Authors:  Richard M van Rijn; Jennifer L Whistler; Maria Waldhoer
Journal:  Curr Opin Pharmacol       Date:  2009-10-19       Impact factor: 5.547

Review 5.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

Review 6.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

7.  Increased morphine analgesia and reduced side effects in mice lacking the tac1 gene.

Authors:  A Bilkei-Gorzo; J Berner; J Zimmermann; R Wickström; I Racz; A Zimmer
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

8.  Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice.

Authors:  Peyman Sahbaie; Xiaoyou Shi; Xiangqi Li; Deyong Liang; Tian-Zhi Guo; Yanli Qiao; David C Yeomans; Wade S Kingery; J David Clark
Journal:  J Pain       Date:  2012-10       Impact factor: 5.820

9.  The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Peg Davis; Shou-wu Ma; Edita Navratilova; Sharif Moye; Josephine Lai; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2008-09-27       Impact factor: 7.446

10.  The beta2 adrenergic receptor regulates morphine tolerance and physical dependence.

Authors:  De-Yong Liang; Xiaoyou Shi; Xiangqi Li; Jun Li; J David Clark
Journal:  Behav Brain Res       Date:  2007-04-07       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.